Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen

Cancer Research

Volumn 57, Issue 20, 1997, Pages 4570-4577

  Zaremba, Sam ^a   Barzaga, Elena ^a   Zhu, Mingzhu ^a   Soares, Nirmolini ^a   Tsang, Kwong Yok ^a   Schlom, Jeffrey ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

AMINO ACID SUBSTITUTION; ANTIGEN SPECIFICITY; ARTICLE; COLON MUCOSA; CYTOTOXIC T LYMPHOCYTE; ENHANCER REGION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; HLA-A2 ANTIGEN; HUMANS; INTERFERON TYPE II; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0030882684     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Muraro, R., Wunderlich, D., Thor, A., Lundy, J., Noguchi, P., Cunningham, R., and Schlom, J. Definition by monoclonal antibodies of a repertoire of epitopes of carcinoembryonic antigen differentially expressed in human colon carcinoma versus normal adult tissues. Cancer Res., 45: 5769-5780, 1985.
2. Steward, A. M., Nixon, D., Zamcheck, N., and Aisenberg, A. Carcinoembryonic antigen in breast cancer patients: serum levels and disease progress. Cancer (Phila.), 33: 1246-1252, 1974.
3. Vincent, R. G., and Chu, T. M. Carcinoembryonic antigen in patients with carcinoma of the lung. J. Thorac. Cardiovasc. Surg., 66: 320-328, 1978.
4. Gold, J. M., Freedman, S. O., and Gold, P. Human anti-CEA antibodies detected by radioimmunoelectrophoresis. Nat. New Biol., 239: 60-62, 1973.
5. Pompecki, R. Presence of immunoglobulin G in human sera binding to carcinoembryonic antigen (CEA) and nonspecific cross-reacting antigen (NCA). Eur. J. Cancer. 16: 973-974, 1980.
6. Ura, Y., Ochi, Y., Hamazu, M., Ishida, M., Nakajima, K., and Watanabe, T. Studies on circulating antibodies against CEA and CEA-like antigen in cancer patients. Cancer Lett., 25: 283-295, 1985.
7. Fuchs, C., Krapf, F., Kern, P., Hoferichter, S., Jager, W., and Kalden, J. K. CEA-containing immune complexes in sera of patients with colorectal and breast cancer: analysis of complexed immunoglobulin classes. Cancer Immunol. Immunother., 26: 180-184, 1988.
8. LoGerfo, P., Herter, F. P., and Bennett, S. J. Absence of circulating antibodies to carcinoembryonic antigen in patients with gastrointestinal malignancies. Int. J. Cancer, 9: 344-348, 1972.
9. MacSween, J. M. The antigenicity of carcinoembryonic antigen in man. Int. J. Cancer. 15: 246-252, 1975.
10. Chester, K. A., and Begent, H. J. Circulating immune complexes (CIC), carcinoembryonic antigen (CEA), and CIC containing CEA as markers for colorectal cancer. Clin. Exp. Immunol., 58: 685-693, 1984.
11. Tsane, K. Y., Zaremba, S., Nieroda, C. A., Zhu, M. Z., Hamilton, J. M., and Schlom, J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst., 87: 982-990, 1995.
12. Gadea, J., Brunette, E., Philip, M., Lyerly, H. K., Philip, R., and Alters, S. Generation of antigen-specific CTL using peptide- and gene-modified dendritic cells. Proc. Am. Assoc. Cancer Res., A3154, 1996.
13. Marshall, J. L., Hawkins, M. J., Richmond, E., Tsang, K., and Schlom,J. A study of recombinant ALVAC-CEA in patients with advanced CEA-bearing cancers. J. Immunother., 19: 461, 1996.
14. Foon, K. A., Chakraborty, M., John, W. J., Sherraft, A., Kohler, H., and Bhattacharya-Chatterjee, M. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J. Clin. Invest., 96: 334-342, 1995.
15. Fagerberg, J., Samanci, A., Yi, Q., Strigard, K., Ryden, U., Wahren, B., and Mellstedt, H. Recombinant carcinoembryonic antigen and granulocyte macrophage colony-stimulating factor for active immunization of colorectal carcinoma patients. J. Immunother., 19: 461, 1996.
16. Conry, R. M., Saleh, M. N., Schlom, J., and LoBuglio, A. F. Human immune response to carcinoembryonic antigen tumor vaccines. J. Immunother., 18: 137, 1995.
17. Parkhurst, M. R., Salgaller, M. L., Southwood, S., Robbins, P. F., Sette, A., Rosenberg, S. A., and Kawakami, Y. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol., 157: 2539-2548, 1996.
18. Salgaller, M. L., Marincola, F. M., Cormier, J. N., and Rosenberg, S. A. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res., 56: 4749-4757, 1996.
19. Bakker, A. B. H., van der Burg, S. H., Huubens, R. J. F., Drijfhout, J. W., Melief, C. J., Adema, G. J., and Figdor, C. G. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. Int. J. Cancer, 70: 302-309, 1997.
20. Pogue, R. R., Eron, J., Frelinger, J. A., and Matsui, M. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proc. Natl. Acad. Sci. USA, 92: 8166-8170, 1995.
21. Lipford, G., Bauer, S., Wagner, H., and Heeg, K. Peptide engineering allows cytotoxic T cell vaccination against human papilloma virus tumor antigen E6. Immunology, 84: 298-303, 1995.
22. Grey, H. M., Ruppert, J., Vitiello, A., Sidney, J., Kast, W. M., Kubo, R. T., and Sette, A. Class I MHC-peptide interactions: structural requirements and functional implications. Cancer Surv., 22: 37-49, 1995.
23. De Magistris, M. T., Alexander, J., Coggeshall, M., Altman, A., Gaeta, F. C. A., Grey, H. M., and Sette, A. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell, 68: 625-634, 1992.
24. Bertoletti, A., Sette, A., Chissari, F. V., Penna, A., Levrero, M., Carli, M. D., Fiaccadori, F., and Ferrari, F. Natural variants of cytotoxic epitopes are T cell receptor antagonists for antiviral cytotoxic T cells. Nature (Lond.), 369: 407-410, 1994.
25. Klenerman, P., Rowland-Jones, S., McAdam, S., Edwards, J., Daenke, S., Lalloo, D., Koppe, B., Rosenberg, W., Boyd, D., Edwards, A., Giangrande, P., Phillips, R. E., and McMichael, A. J. Cytotoxic T cell activity antagonized by naturally occurring HIV-1 gag variants. Nature (Lond.), 369: 403-407, 1994.
26. Kuchroo, V. K., Greer, J. M., Kaul, D., Ishioka, G., Franco, A., Sette, A., Sobel, R. A., and Lees, M. B. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J. Immunol., 153: 3326-3336, 1994.
27. Jameson, S. C. and Bevan, M. J. T cell receptor antagonists and partial agonists. Immunity, 2: 1-11, 1995.
28. Meier, U-C., Klenerman, P., Griffin, P., James, W., Koppe, B., Larder, B., McMichael, A., and Phillips, R. Cytotoxic T lymphocyte lysis inhibited by viable HIV mutants. Science (Washington, DC), 270: 1360-1362, 1995.
29. Chen, Y., Matsushita, S., and Nishimura, Y. Response of a human T cell clone to a large panel of altered peptide ligands carrying single-residue substitutions in an antigenic peptide: characterization and frequencies of TCR agonism and TCR antagonism with or without partial activation. J. Immunol., 157: 3783-3790, 1996.
30. Nijman, H. W., Houbiers, J. G., Vierboom, M. P., van der Hurg, S. H., Drijfhout, J. W., D'Amaro, J., Kenemans, P., Melief, C. J., and Kast, W. M. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur. J. Immunol., 23: 1215-1219, 1993.
31. Rammensee H-G., Friede, T. and Stevanovic, S. MHC ligands and peptide motifs: first listing. Immunogenetics, 41: 178-228, 1995.
32. Ruppert, J., Sidney, J., Celis, E., Kubo, R. T., Grey, H. M., and Sette, A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell, 74: 929-937, 1993.
33. Madden, D. R., Garboczi, D. N., and Wiley, D. C. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell, 75: 693-708, 1993.
34. Hamilton, J. M., Chen, A. P., Nguyen, B., Grem, J., Abrams, S., Chung, Y., Kantor, J., Phares, J. C., Bastian, A., Brooks, C., Morrison, G., Allegra, C. J., and Schlom, J. Phase I siudy of recombinant vaccinia virus (rV) that expresses human carcinoembryonic antigen (CEA) in adult patients with adenocarcinomas. Proc. Am. Soc. Clin. Oncol., 961, 1994.
35. Abrams, S. I., Horan Hand, P., Tsang, K. Y., and Schlom, J. Mutant ras epitopes as targets for cancer vaccines. Semin. Oncol., 23: 118-134, 1996.
36. Elas, A. V., Nijman, H. W., Van Minne, C. E., Mourer, J. S., Kast, W. M., Melief, C. J. M., and Schrier, P. I. Induction and characterization of cytotoxic T lymphocytes recognizing a mutated p21 RAS peptide presented by HLA-A2010. Int. J. Cancer, 61: 389-396, 1995.
37. Houbiers, J. G. A., Nijman, H. W., van der Burg, S. H., Drijfhout, J. W., Kenemans, P., van de Velde, C. J. H., Brande, A., Momburg, F., Kast, W. M., and Melief, C. J. M. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol., 23: 2072-2077, 1993.
38. Ropke, M., Regner, M., and Claesson, M. H. T cell-mediated cytotoxicity against p53 protein-derived peptides in bulk and limiting dilution cultures of healthy donors. Scand. J. Immunol., 42: 98-103, 1995.
39. Robbins, P. F., El-Gamil, M., Li, Y. F., Kawakami, Y., Loftus, D., Appella, E., and Rosenberg, S. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor-infiltrating lymphocytes. J. Exp. Med., 183: 1185-1192, 1996.
40. Skipper, J. C. A., Hendrickson, R. C., Gulden, P. H., Brichard, V., van Pei, A., Chen, Y., Shabanowitz, J., Wolfel, T., Slingluff, C. L., Jr., Boon, T., Hunt, D. F., and Engelhard, V. H. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from post-translational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med., 183: 527-534, 1996.
41. Thompson, J. A., Grunert, F., and Zimmerman, W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J. Clin. Lab. Anal., 5: 344-366, 1991.
42. Van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., and Boon, T. A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma. Science (Washington DC), 254: 1643-1647, 1991.
43. Kawakami, Y., Eliyahu, S., Delgaldo, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., and Rosenberg, S. A. Cloning of the gene coding for a shared human melanocyte antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA, 91: 3515-3519, 1994.
44. Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, I., and Eberlein, T. J. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA, 92: 432-436, 1995.
45. Matsuoka, T., Kohrogi, H., Ando, M., Nishimura, Y., and Matsushita, S. Altered TCR ligands affect antigen-presenting cell responses: up-regulation of IL-12 by analogue peptide. J. Immunol., 157: 4837-4843, 1996.
46. Ikagawa, S., Matsushita, S., Chen, Y-Z., Ishikawa, T., and Nishimura, Y. Single amino acid substitutions on a Japanese cedar pollen allergen (Cry j 1)-derived peptide induced alterations in human T cell responses and T cell receptor antagonism. J. Allergy Clin. Immunol., 97: 53-64, 1996.
47. England, R. D., Kullberg, M. C., Cornette, J. L., and Berzofsky, J. A. Molecular analysis of a heteroclitic T cell response to the immunodominant epitope of sperm whale myoglobin: implications for peptide partial agonists. J. Immunol., 155: 4295-4306, 1995.
48. Ropke, M., Hald, J., Guldberg, P., Zeuthen, J., Norgaard, L., Fugger, L., Svejgaard, A., Van Der Burg, S., Nijman, H. W., Melief, C. J. M., and Claesson, M. H. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc. Natl. Acad. Sci. USA, 93: 14704-14707, 1996.
49. Correale, P., Walmsley, K., Nieroda, C., Zaremba, S., Zhu, M., Schlom, J., and Tsang, K. Y. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. Natl. Cancer Inst., 89: 293-300, 1997.
50. Chen, W., Ede, N. J., Jackson, D. C., McCluskey, J., and Purcell, A. W. CTL recognition of an altered peptide associated with asparagine bond rearrangement: implications for immunity and vaccine design. J. Immunol., 157: 1000-1005, 1996.
51. Kersh, G. J., and Allen, P. M. Structural basis for T cell recognition of altered peptide ligands: a single T cell receptor can productively recognize a large continuum of related ligands. J. Exp. Med., 184: 1259-1268, 1996.